George Grigoriadis

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa

Mohammad Al‐Tamimi, George Grigoriadis, Huy Tran et al. · Blood · 2011 · 92 citations · Full text

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

Pasquale L. Fedele, Simon N. Willis, Yang Liao et al. · Blood · 2018 · 87 citations · Full text

The Transcription Factors c-rel and RelA Control Epidermal Development and Homeostasis in Embryonic and Adult Skin via Distinct Mechanisms

Raffi Gugasyan, Anne K. Voss, George Varigos et al. · Molecular and Cellular Biology · 2004 · 80 citations · Full text

Distinct Mechanisms, Cell Proliferation, Adult Skin +19